D e s i g n
Randomized (allocation concealed*), blinded (outcome assessor, {patients, and clini-cians} †),* placebo-controlled trial with a mean follow-up of 1 year. S e t t i n g 313 investigational sites in the United States and 13 European countries. P a t i e n t s 3991 patients (mean age 64 y, 78% men) who had had symptomatic heart failure (New York Heart Association [NYHA] class II to IV) for ≥ 3 months, a decreased ejection fraction (≤ 0.40), and a resting heart rate ≥ 68 beats/min and had received optimal treatment for ≥ 2 weeks before randomization. Exclusion criteria included acute myocardial infarction or unstable angina pectoris ≤ 28 days before randomization, indication or contraindication for β 1 -blockers, severe decompensated heart failure, or supine systolic blood pressure < 100 mm Hg. Patients with an ejection fraction between 0.36 and 0.40 were excluded if they exceeded 500 yards in a 6-minute walk test. All patients were included in the analysis.
I n t e r v e n t i o n
Patients were allocated to metoprolol (n = 1990) or placebo (n = 2001). The dose was started at 25 mg/d (12.5 mg/d for patients with NYHA class III or IV) and doubled every 2 weeks until the target dose of 200 mg/d was reached.
M a i n o u t c o m e m e a s u r e s
All-cause mortality or any hospital admission, hospitalization for worsening heart failure, and change in NYHA class.
M a i n r e s u l t s
Analysis was by intention to treat. The study was stopped early because interim analysis showed a 34% reduction in mortality. Fewer patients in the metoprolol group than in the placebo group died or were hospitalized (P < 0.001) or were hospitalized for worsening heart failure (P < 0.001) (Table) . Patients in the metoprolol group were more likely to improve by 1 NYHA class (26% vs 24%) or 2 NYHA classes (2.6% vs 1.5%) and were less likely to deteriorate in NYHA class than were patients in the placebo group (P = 0.003 for trend).
C o n c l u s i o n
In patients with symptomatic chronic heart failure, controlled-and extended-release metoprolol reduced mortality, hospital admissions, and symptoms. 
C o m m e n t a r y
Our understanding of systolic heart failure in the past decade has evolved through a series of models, from cardiorenal (diuretics), to hemodynamic (inotropic and vasodilator therapy), to the more recent neurohormonal model. The earlier models all achieved the basic clinical need of symptomatic relief, but only the neurohormonal model has addressed morbidity and survival benefits. The earlier conceptual models labeled β-blockade as counterintuitive therapy, but β-blockers are now mandated in conjunction with angiotensin-converting enzyme (ACE) inhibitors in patients who have chronic heart failure with systolic dysfunction. Even in the face of overwhelming data supporting the use of β-blockers, it is important to apply clinical caution: β-blockade must not be begun in the presence of overtly decompensated heart failure; a "start low and go slow" regimen should be followed; close clinical follow-up for signs of decompensation during titration must be maintained; and severe class IV heart failure is usually still a contraindication for β-blockade because of little supportive evidence.
Unlike ACE inhibitors for which a class effect has been shown, different β-blockers still appear to evoke some heterogeneity in their responses. The most validated adrenergic blockers in heart failure include carvedilol, metoprolol CR/XL, and bisoprolol. Little evidence exists for the benefit of other β-blockers in chronic heart failure. 
